<div id="readability-page-1"><p>Artemis Investment Management LLP purchased a new stake in  Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund purchased 1,740,753 shares of the biopharmaceutical company's stock, valued at approximately $93,896,000. Bristol Myers Squibb makes up  approximately  1.1% of Artemis Investment Management LLP's investment portfolio, making the stock its 25th largest holding. Artemis Investment Management LLP owned approximately 0.09% of Bristol Myers Squibb at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><ul><li>2 Buffett Stocks to Load Up On—And 1 to Ditch</li></ul><p>A number of other institutional investors have also made changes to their positions in the business. Darwin Wealth Management LLC acquired a new stake in shares of  Bristol Myers Squibb in the second quarter valued at approximately $25,000.  Physician Wealth Advisors Inc. lifted its position in shares of  Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 202 shares during the last quarter.  EQ Wealth Advisors LLC acquired a new stake in shares of  Bristol Myers Squibb in the fourth quarter valued at approximately $32,000.  KERR FINANCIAL PLANNING Corp acquired a new stake in shares of  Bristol Myers Squibb in the third quarter valued at approximately $35,000.  Finally, JPL Wealth Management LLC acquired a new stake in shares of  Bristol Myers Squibb in the third quarter valued at approximately $36,000. Institutional investors own  76.41% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>BMY has been the topic of several research analyst reports. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a &#34;sector perform&#34; rating and a $60.00 price objective on the stock. HSBC increased their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a &#34;hold&#34; rating in a research note on Tuesday, March 17th. Leerink Partners raised their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, January 13th. Wells Fargo &amp; Company  reaffirmed an &#34;outperform&#34; rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Morgan Stanley  restated an &#34;underweight&#34; rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat, the stock  has an average rating of &#34;Hold&#34; and a consensus price target of $61.31.</p><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p><b>View Our Latest Research Report on Bristol Myers Squibb</b></p><h2>Insider Activity at Bristol Myers Squibb</h2><p>In other news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own  0.05% of the company's stock. </p><h2>Key Bristol Myers Squibb News</h2><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p>Here are the key news stories impacting Bristol Myers Squibb this week:</p><ul>   <li><span>Positive Sentiment: </span>BMY posted a Q1 beat — $1.58 EPS vs. consensus ~$1.42 and $11.49B revenue — driven by growth drugs and Eliquis outperformance, which supports near‑term cash flow. <i></i><span>Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales</span></li>    <li><span>Positive Sentiment: </span>Management reiterated FY outlook and emphasized the “growth portfolio” (Breyanzi, Camzyos) and cost‑cutting progress as drivers of durable margin improvement. <i></i><span>Bristol-Myers Squibb Signals Confident Path After Q1 Call</span></li>    <li><span>Positive Sentiment: </span>Pipeline catalysts could lift long‑term growth: Phase III readouts for milvexian (potential Eliquis successor) and Cobenfy (schizophrenia) are highlighted as multi‑year drivers. <i></i><span>BMS brings the buzz around late-stage readouts amid a so-so Q1</span></li>    <li><span>Neutral Sentiment: </span>Analysts’ consensus price target sits near $61.31, indicating limited upside from current levels absent new positive catalysts. <i></i><span>Bristol Myers Squibb Company <span>NYSE: BMY<span></span></span> Receives $61.31 Consensus PT from Analysts</span></li>    <li><span>Negative Sentiment: </span>FY 2026 guidance (EPS 6.05–6.35; revenue $46.0–47.5B) left the revenue midpoint slightly below the Street, tempering upside after the quarter and contributing to profit‑taking. <i></i><span>Bristol Myers Squibb Reports First Quarter Financial Results for 2026</span></li>    <li><span>Negative Sentiment: </span>Analysts/coverage notes emphasize the scale of the Eliquis patent cliff (multi‑billion dollar risk over coming years), which pressures valuation beyond near‑term beats. <i></i><span>Thinning revenues: inside the $14bn Eliquis patent cliff</span></li>    <li><span>Negative Sentiment: </span>Bernstein maintained a Hold rating, signaling that some investors and analysts want clearer evidence that growth and pipeline will offset legacy declines. <i></i><span>Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)</span></li> </ul><h2>Bristol Myers Squibb Trading Down 3.9%</h2><p>Shares of BMY stock opened at $58.24 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The firm has a market capitalization of $118.92 billion, a P/E ratio of 16.88, a P/E/G ratio of 0.17 and a beta of 0.26. The stock's fifty day simple moving average is $59.56 and its 200 day simple moving average is $54.48. </p><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 66.57%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the firm posted $1.80 EPS. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.  As a group, sell-side analysts predict that  Bristol Myers Squibb Company will post 6.27 EPS for the current fiscal year. </p><h2>Bristol Myers Squibb Dividend Announcement</h2><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio  is currently 73.04%. </p><h2>Bristol Myers Squibb Profile</h2> (Free Report)<p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.  </p><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p><h2>See Also</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li></ul><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>Artemis Investment Management LLP has acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY), purchasing 1,740,753 shares valued at approximately $93.9 million during the fourth quarter. This investment represents about 1.1% of Artemis's portfolio, making BMY its 25th largest holding. Other institutional investors have also increased their stakes in the company. Analysts have mixed ratings on BMY, with a consensus price target of $61.31. Recent positive earnings and growth prospects have been noted, although some analysts express caution regarding future upside.</p>

Market Beat

Bristol Myers Squibb

Ark Genomic Revolution ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

Direxion Pharma & Medical Bull 3X

VanEck Biotech ETF

iShares US Pharma

VG Health

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

ProShares Ultra Health Care ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Artemis Resources Limited

Apartment Investment

Artisan Partners Asset Management 

Nano Labs

Wealth Management Inc

Wtree Intl Eq

Wtree Dy Curr Hdg Intl Eq

Wealthfront

COtwo Advs Physical Eur Carb AllowanceTr

EQ HEALTH ACQUISITION CORP C/WTS 02/02/2028 (TO PUR COM)

Kearny Financial

Kilroy Realty

Daishinku Corp.,

WealthNavi, Inc.

Jupiter Fund Management plc

ROYAL BANK OF CANADA

Bank of Montreal

Canadian Imperial Bank Comm

HSBC

HSBC HOLDINGS

HSBC Holdings Plc

TRUE PARTNER

PC Partner

Ai Partners Financial Inc.

Wells Fargo

Morgan Stanley

GRAIL

Bristol-Myers Squibb Company

HSBC 5xShortSG241213

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Artemis Investment Management LLP Takes Position in Bristol Myers Squibb Company $BMY